Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 15/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.67 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12569790 | 0.92 | OPRD1 (0.79) | OPRD1KCNH2OPRK1OPRM1 | |
| SCHEMBL12569786 | 0.92 | OPRD1 (0.79) | OPRD1KCNH2OPRK1OPRM1 | |
| SCHEMBL6268005 | 0.88 | OPRD1 (0.85) | OPRD1KCNH2OPRK1OPRM1 | |
| SCHEMBL6236576 | 0.87 | OPRD1 (0.58) | OPRD1KCNH2OPRK1OPRM1 | |
| SCHEMBL2002716 | 0.87 | OPRD1 (0.71) | OPRD1KCNH2OPRK1OPRM1 | |
| SCHEMBL5522677 | 0.87 | OPRD1 (0.65) | OPRD1KCNH2OPRK1OPRM1 | |
| SCHEMBL5522686 | 0.87 | OPRD1 (0.65) | OPRD1KCNH2OPRK1OPRM1 | |
| SCHEMBL1998734 | 0.86 | OPRD1 (0.65) | OPRD1KCNH2OPRK1OPRM1 | |
| SCHEMBL1998738 | 0.86 | OPRD1 (0.65) | OPRD1KCNH2OPRK1OPRM1 | |
| SCHEMBL1999813 | 0.86 | OPRD1 (0.64) | OPRD1KCNH2OPRK1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960389-B2 | 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
| US-20070254890-A1 | 4(Phenyl-Piperazinyl-Methyl) Benzamide Derivatives and Their Use for the Treatment of Pain or Gastrointestinal Disorders | ASTRAZENECA AB (SE) | 2007-11-01 | — | — | US | disclosed |
| US-7253173-B2 | 4(Phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain of gastrointestinal disorders | ASTRAZENECA AB (SE) | 2007-08-07 | — | — | US | disclosed |
| US-20060122193-A1 | 4(Phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | disclosed |
| EP-1562924-A1 | 4(PHENYL-PIPERAZINYL-METHYL) BENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PAIN OR GASTROINTESTINAL DISORDERS | AstraZeneca AB (SE) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004041802-A1 | 4(PHENYL-PIPERAZINYL-METHYL) BENZAMIDE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PAIN OR GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122193-A1 | 4(Phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders | OPRK1, TRPV1, OPRM1 | OPRD1 5/4885KCNH2 217/4885OPRK1 1/4885 |
| US-20070254890-A1 | 4(Phenyl-Piperazinyl-Methyl) Benzamide Derivatives and Their Use for the Treatment of Pain or Gastrointestinal Disorders | TRPV1, OPRM1, OPRK1 | OPRD1 6/4885KCNH2 189/4885OPRK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.